16 research outputs found
A 10 year study of hospitalized atrial fibrillation-related stroke in England and its association with uptake of oral anticoagulation
Aims: To determine whether changing patterns of anticoagulant use in atrial fibrillation (AF) have impacted on stroke rates in England.
Methods and results: English national databases, 2006–2016, were interrogated to assess stroke admissions and oral anticoagulant use. The number of patients with known AF increased linearly from 692 054 to 983 254 (prevalence 1.29% vs. 1.71%). Hospital episodes of AF-related stroke/100 000 AF patients increased from 80/week in 2006 to 98/week in 2011 and declined to 86/week in 2016 (2006–2011 difference 18.0, 95% confidence interval (CI) 17.9–18.1, 2011–2016 difference −12.0, 95% CI −12.1 to −11.9). Anticoagulant use amongst patients with CHA2DS2-VASc ≥2 increased from 48.0% to 78.6% and anti-platelet use declined from 42.9% to 16.1%; the greatest rate of change occurred in the second 5 year period (for anticoagulants 2006–2011 difference 4.8%, 95% CI 4.5–5.1%, 2011–2016 difference 25.8%, 95% CI 25.5–26.1%). After adjustment for AF prevalence, a 1% increase in anticoagulant use was associated with a 0.8% decrease in the weekly rate of AF-related stroke (incidence rate ratio 0.992, 95% CI 0.989–0.994). Had the use of anticoagulants remained at 2009 levels, 4068 (95% CI 4046–4089) more strokes would have been predicted in 2015/2016.
Conclusion: Between 2006 and 2016, AF prevalence and anticoagulant use in England increased. From 2011, hospitalized AF-related stroke rates declined and were significantly associated with increased anticoagulant uptake
Current strategies of anticoagulation therapy for patients with non-valvular atrial fibrillation
Impact of B-type natriuretic peptide (BNP) on development of atrial fibrillation in people with Type 2 diabetes
Administration of Antiarrhythmic Drugs to Maintain Sinus Rhythm After Catheter Ablation for Atrial Fibrillation: A Meta-Analysis
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
17restrictedrestrictedKirchhof P; Benussi S; Kotecha D; Ahlsson A; Atar D; Casadei B; Castella M; Diener HC; Heidbuchel H; Hendriks J; Hindricks G; Manolis AS; Oldgren J; Popescu BA; Schotten U; Van Putte B; Vardas PKirchhof, P; Benussi, S; Kotecha, D; Ahlsson, A; Atar, D; Casadei, B; Castella, M; Diener, Hc; Heidbuchel, H; Hendriks, J; Hindricks, G; Manolis, As; Oldgren, J; Popescu, Ba; Schotten, U; Van Putte, B; Vardas,